(Q38205707)

31 August 2017

title

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials (English)

1 reference

31 August 2017

0 references

1 reference

Andrea Giusti

1

1 reference

31 August 2017

language of work or name

1 reference

21 April 2014

1 reference

Journal of Bone and Mineral Metabolism

31 August 2017

published in

1 reference

31 August 2017

volume

32

1 reference

31 August 2017

issue

6

1 reference

31 August 2017

page(s)

606-615

1 reference

https://scigraph.springernature.com/pub.10.1007/s00774-014-0584-8

31 August 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Bone disease and skeletal complications in patients with β thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Bone disease in thalassemia: a frequent and still unresolved problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Prevalence of fractures among the Thalassemia syndromes in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Use of bisphosphonates in the management of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Bisphosphonates: how do they work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Bisphosphonates in the treatment of thalassemia-induced osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-014-0584-8

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

21 January 2018

1 reference

12 December 2020

Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial

1 reference

12 December 2020

High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density

1 reference

12 December 2020

Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study

1 reference

12 December 2020

Bone disease in beta-thalassaemia major

1 reference

12 December 2020

The influence of treatment in specialized centers on survival of patients with thalassemia major

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia

1 reference

12 December 2020

Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major.

1 reference

12 December 2020

Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial

1 reference

12 December 2020

10.1007/S00774-014-0584-8

Identifiers

DOI

1 reference

31 August 2017

1 reference